Long-term safety of lisocabtagene maraleucel in patients with relapsed follicular lymphoma
Official title: Non-interventional Cohort Study of Patients Treated With Liso-cel (Lisocabtagene Maraleucel) for Relapsed/Refractory Follicular Lymphoma in the Postmarketing Setting
Run by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT06794268 · Data updated 2026-11-12
This study is testing the long-term safety of a treatment called lisocabtagene maraleucel in people with relapsed follicular lymphoma who have already received it.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company Industry-sponsored |
| Drugs / interventions | chimeric antigen receptor |
| Locations | 1 site (Milwaukee, Wisconsin) |
| Status | Recruiting |
| Started | February 4, 2025 |
| Main results expected | August 31, 2044 |
| Study ends | August 31, 2044 |
| Registry record updated | February 24, 2025 |
| Trial ID | NCT06794268 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients with relapsed or refractory follicular lymphoma who have received liso-cel treatment in accordance with FDA-approved guidelines.
✕Probably not a fit
Patients treated with liso-cel for follicular lymphoma Grade 3b or those participating in other investigational studies may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to evaluate the long-term safety of lisocabtagene maraleucel (liso-cel) in patients who have been treated for relapsed or refractory follicular lymphoma. It focuses on individuals who have received at least one infusion of liso-cel in a post-marketing setting, contributing to pharmacovigilance efforts. The study will collect data on patient outcomes and safety profiles to better understand the treatment's effects over time.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the long-term safety and effectiveness of liso-cel for patients with follicular lymphoma.
How similar studies have gone: While this study focuses on post-marketing safety, similar studies evaluating CAR T-cell therapies have shown promising results in terms of safety and efficacy.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: • Participants must have been treated in the post-marketing setting with at least 1 infusion of lisocabtagene maraleucel (liso-cel) used for the treatment of relapsed/refractory (R/R) follicular lymphoma (FL), including FL Grade 1, Grade 2 and Grade 3a, within the FDA-approved indication and dosage per the United States Prescribing Information (USPI) and product specifications approved for commercial release in the USA Exclusion Criteria: * Participants known to be participating in investigational studies at the time of liso-cel, infusion * Participants treated with liso-cel for the treatment of R/R FL Grade 3b * Participants treated with non-conforming chimeric antigen receptor (CAR) T-cell product
Where it's running
-
Cibmtr
Milwaukee, Wisconsin, United States Recruiting
Study contacts
- Study coordinator: BMS Study Connect Contact Center www.BMSStudyConnect.com
- Email: Clinical.Trials@bms.com
- Phone: 855-907-3286
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Non-Hodgkin Lymphoma Sample Collection for MRD Testing
This study tests a blood-based and tissue-based approach to see if a molecular residual disease test can detect lingering cancer in adults with aggressive NHL who are starting standard therapy.
-
MK-1045 and Rituximab in Follicular Lymphoma
This study tests whether adding MK-1045 to rituximab can help people with follicular lymphoma after standard therapy.
-
Mosunetuzumab and Zeprumetostat in Follicular Lymphoma
This study tests whether a combination of Mosunetuzumab and Zeprumetostat can help adults with follicular lymphoma.
-
Zanubrutinib plus obinutuzumab and lenalidomide for first-line follicular lymphoma
This trial tests whether the combination of zanubrutinib, obinutuzumab, and lenalidomide is safe and effective as a chemotherapy-free first treatment for adults with untreated follicular lymphoma.
-
LY4584180 with rituximab for adults with previously treated B‑cell lymphomas
This trial will test LY4584180 together with rituximab in adults with previously treated B‑cell lymphomas to see if it is safe, reaches useful levels in the blood, and can help control the disease.
-
Rituximab and Tafasitamab with Allogeneic NK Cells for relapsed or refractory B-cell NHL
This trial tests whether giving allogeneic NK cells with Rituximab, Tafasitamab, and IL-2 can help people with relapsed or refractory B-cell non-Hodgkin lymphoma who have tried at least two prior therapies.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.